| |
No discontinuation
|
Failures excluded
|
Failures switched
|
|---|
| |
Exenatide
|
Glargine
|
Δ
|
Exenatide
|
Glargine
|
Δ
|
Exenatide
|
Glargine
|
Δ
|
|---|
|
Macrovascular
|
|
Ischaemic Heart Disease
|
122.2
|
121.2
|
-1.06
|
111.1
|
121.4
|
10.32
|
121.8
|
121.4
|
-0.36
|
|
Myocardial Infarction
|
387.4
|
388.2
|
0.82
|
351.9
|
387.7
|
35.79
|
386.1
|
387.7
|
1.61
|
|
Congestive heart Failure
|
84.9
|
92.6
|
7.68
|
77.7
|
92.3
|
14.59
|
85.4
|
92.3
|
6.87
|
|
Stroke
|
98.9
|
99.7
|
0.74
|
90.1
|
98.3
|
8.19
|
99.2
|
98.3
|
-0.89
|
|
Microvascular
|
|
Retinopathy
|
55.5
|
55.4
|
-0.03
|
50.7
|
55.4
|
4.73
|
55.3
|
55.4
|
0.11
|
|
Nephropathy
|
14.1
|
13.8
|
-0.29
|
12.7
|
14.1
|
1.41
|
14.1
|
14.1
|
-0.01
|
|
Neuropathy
|
12.9
|
12.9
|
0.04
|
11.8
|
12.9
|
1.13
|
13.1
|
12.9
|
-0.14
|
|
Hypoglycaemia events
|
|
Nocturnal
|
12901.2
|
34259.8
|
21358.6
|
11754.3
|
34269.6
|
22515.3
|
14804.9
|
34269.6
|
19464.7
|
|
Symptomatic
|
94479.7
|
55672.2
|
-38807.5
|
86080.9
|
55688.1
|
-30392.8
|
91090.4
|
55688.1
|
-35402.3
|
|
Severe
|
6622.0
|
6597.5
|
-24.5
|
6036.2
|
6598.1
|
561.9
|
6626.2
|
6598.1
|
-28.2
|
|
Fatal
|
|
Macrovascular
|
453.5
|
458.2
|
4.68
|
412.8
|
457.3
|
44.53
|
453.3
|
457.282
|
4.008
|
|
Microvascular
|
12.7
|
12.7
|
-0.02
|
11.6
|
12.8
|
1.18
|
12.9
|
12.752
|
-0.154
|
|
Other
|
532.8
|
528.1
|
-4.68
|
486.0
|
529.0
|
42.99
|
532.8
|
529.0
|
-3.845
|
|
Cost effectiveness
|
|
Discounted costs
|
£14,567,526
|
£9,280,312
| |
£13,255,912
|
£9,296,371
| |
£14,092,624
|
£9,296,371
| |
|
Discounted QALYS
|
7,683
|
7,864
| |
7,000
|
7,865
| |
7,703
|
7,865
| |
|
ICER (£/QALY)
|
Dominant (-£29,149)
|
Dominant (-£4,579)
|
Dominant (-£29,657)
|
- Note: the model takes an average of a series of runs in order for the resultant values to become stable. In taking this average non-integer values can be generated.
